The figure also highlights various NY‐ESO‐1‐based cancer vaccine approaches, including protein/peptide‐based, RNA/DNA‐based, artificial adjuvant vector cells‐based and microbial vector‐based strategies, all of which are designed to enhance immune responses against tumours expressing NY‐ESO‐1. Here, CTAG1B is linked to neoplasm.